Abstracts tagged "IL-23"

Abstract Number: 1014 • 2019 ACR/ARP Annual Meeting
Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients
Siba Raychaudhuri¹ and Smritikana Raychaudhuri ², ¹UC Davis School of Medicine, Sacramento, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: Here we hypothesized that (i) IL-23/IL-23R system more specifically the specific IL-23p19 subunit mediated signaling system regulates expansion/maintenance and functional maturation in respect to…
Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Daniele Mauro¹, Federica Macaluso ², Alessandra Nerviani ³, Marie-Astrid Boutet ³, Aroldo Rizzo ⁴, Riccardo Alessandro ², Giuliana Guggino ², Costantino Pitzalis ³ and Francesco Ciccia ⁵, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, ²University of Palermo, Italy, Palermo, Italy, ³Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, ⁵University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting
Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders
Jeffrey Crowley¹, Kim A Papp², Chih-ho Hong³, Jeff Parno⁴, Alan M Mendelsohn⁴, Qing Li⁵ and Nicole Cichanowitz⁵, ¹Bakersfield Dermatology, Bakersfield, CA, ²Probity Medical Research, Waterloo, ON, Canada, ³University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁵Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting
Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
Melinda Gooderham¹, Boni E. Elewski², David M. Pariser³, Howard Sofen⁴, Alan M Mendelsohn⁵, Nicole Cichanowitz⁶ and Qing Li⁶, ¹Probity Medical Research, and Skin Center for Dermatololgy, Waterloo, and Peterborough, ON, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, ⁴Ronald Reagan UCLA Medical Center, Department of Medicine (Dermatology) UCLA, Los Angeles, CA, ⁵Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ
Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…
Abstract Number: 62 • 2018 ACR/ARHP Annual Meeting
CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis
W Razawy¹, N Salioska², P Asmawidjaja³, A Otten-Mus⁴, N Kops⁵, M Oukka⁶, V Kuchroo⁷ and Erik Lubberts³, ¹Rheumatology and Immunology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology, Erasmus MC, Rotterdam, Netherlands, ³Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵Orthopedics, Erasmus MC, Rotterdam, Netherlands, ⁶Pediatrics, Seattle Children's Research Institute, Seattle, WA, ⁷Center for Neurologic Diseases, Harvard Institute of Medicine, Boston, MA
Background/Purpose: The IL-23/IL-17A immune pathway is important for the progression of T cell-mediated arthritis. However, it is not known where IL-23R+ T cells locate during…
Abstract Number: 143 • 2018 ACR/ARHP Annual Meeting
Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Benjamin D. Korman², Judilyn Duculan³, Mayte Suarez-Farinas⁴, James G. Krueger³ and Christopher T. Ritchlin², ¹Department of Medicine, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ²Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ³Laboratory for Investigative Dermatology, Rockefeller University, New York City, New York, USA, New York City, NY, ⁴Icahn School of Medicine at Mount Sinai, New York City, New York, USA, New York City, NY
Background/Purpose: Th17, a subset of CD4+ helper T cells, provides protection against pathogens and malignancies, but also promotes immune-mediated-inflammation in a range of disorders including…
Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
Qingxuan Song, Matthew Loza, Karen Leander, Brittney Scott, Patrick Branigan and Kristen Sweet, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…
Abstract Number: 1028 • 2018 ACR/ARHP Annual Meeting
An Entheseal Innate Immune Cell Biological Basis for Differential Efficacy of PDE4 and IL-23 Pathway Blockade between Psoriatic Disease and Rheumatoid Arthritis
Charlie Bridgewood¹, Richard Cuthbert¹, Abdulla Watad², Tobias Russell¹, Timothy Palmer³, Robert Dunsmuir⁴, Almas Khan⁴, Abhay Rao⁴, Miriam Wittmann⁵ and Dennis McGonagle¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Department of Internal Medicine 'B', Sheba Medical Center, Ramat Gan, Ramat Gan, Israel, ³School of Pharmacy and Medical Sciences, University of Bradford, Bradford, United Kingdom, ⁴Department of Spinal Surgery, National Health Service, Leeds, United Kingdom, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Both IL-23 and phosphodiesterase (PDE) 4 inhibition are ineffective in RA but show efficacy in PsA-related synovitis despite similar cytokine and molecular profiles between…
Abstract Number: 2021 • 2018 ACR/ARHP Annual Meeting
Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis
Sandeep Kansurkar¹, Ankita Singh², Ramnath Misra³ and Amita Aggarwal³, ¹Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-17 and IL-22 are important cytokines in pathogenesis of spondyloarthropathy. In an IL-23 or IL-22 over-expressing mouse model it was shown that enthesitis is…
Abstract Number: 2L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Philip J Mease¹, Herbert Kellner², Akimichi Morita³, Alan J. Kivitz⁴, Kim A. Papp⁵, Stella Aslanyan⁶, Beate Berner⁷, Kun Chen⁸, Ann Eldred⁸ and Frank Behrens⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Private Practice and Division of Rheumatology KHI Neuwittelsbach, München, Germany, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…
Abstract Number: 645 • 2017 ACR/ARHP Annual Meeting
An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis
Eric Gracey^1,2, Melissa Lim², Zoya Qaiyum¹, Yuriy Baglaenko^1,2, Wenyan Miao³, Craig Masse³, William Westlin³ and Robert D Inman^1,4, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Nimbus Therapeutics, Cambridge, MA, ⁴Toronto Western Hospital, University Health Network, toronto, ON, Canada
Background/Purpose: Th17 cells play an important role in the pathogenesis of ankylosing spondylitis (AS). Tyk2, a member of the Janus Kinase (JAK) family of signaling…
Abstract Number: 659 • 2017 ACR/ARHP Annual Meeting
IL-17 Producing T Cells and Its Dichotomy: A Mixed Response of the Innate and Acquired Immune System in Psoriatic Arthritis
Siba P. Raychaudhuri¹ and Smriti K. Raychaudhuri², ¹Rheumatology Section, Sacramento Veterans Affairs Medical Center, Sacramento, CA, ²Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: Source of IL-17 in human has been mainly attributed to ab T cells, more specifically to the Th17 cells. However, some reports suggest…
Abstract Number: 660 • 2017 ACR/ARHP Annual Meeting
Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis
Imtiyaz Hossain, Mederbek Matmusaev and Joerg Ermann, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydrodynamic injection of IL-23 minicircles into adult B10.RIII mice induces an inflammatory disease with phenotypic features of human spondyloarthritis. Tissue-resident CD4-CD8- double negative (DN)…
Abstract Number: 1576 • 2017 ACR/ARHP Annual Meeting
IL-23 Promotes Fecal Microbiota Dysbiosis Associated with Susceptibility to Spondyloarthritis and Ileitis in ZAP-70 Mutant SKG Mice
Linda Rehaume¹, Nicholas Matigian¹, Kate Ormerod², Alicia Kang¹, Richard Linedale¹, Olga Zbarskaya¹, Kristine Kikly³, Joshua Daly², Nancy Lachner², Philip Hugenholtz², Mark Morrison¹, Kim-Anh Lê Cao⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ²Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, ³Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, ⁴School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia
Background/Purpose: Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from SpA, or for people at-risk of disease…
Abstract Number: 1578 • 2017 ACR/ARHP Annual Meeting
The Initiation, but Not the Persistence, of Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats Is Crucially Dependent on the IL-23 Axis
Melissa van Tok^1,2, Songqing Na³, Joel Taurog⁴, Dominique Baeten^2,5 and Leonie van Duivenvoorde^1,2, ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Eli Lilly and Company, Indianapolis, IN, ⁴Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A is a central driver of spondyloarthritis (SpA) pathology. IL-17A production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.